Clinical trials: MDI
Type 1 Diabetes Mellitus
A Study of t:Slim X2 With Control-IQ Technology
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for children with type 1 diabetes can safely improve blood glucose (sometimes called blood sugar) control.
- Trial name
- DCLP5 (NCT03844789)
- Testing
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Control Group
- Where
- 4 sites in United States
- Volunteers
- 101 people
- Sponsor
- University of Virginia
Asthma, Patient Compliance
Using Information Technology to Improve Asthma Adherence
The purpose of this study is to determine whether providing patient medication adherence information on inhaled corticosteroid use to clinicians will result in improved patient adherence and asthma control.
- Trial name
- AFFIRM (NCT00459368)
- Testing
- Feedback of patient adherence information, Active control group
- Where
- United States
- Volunteers
- 2,698 people
- Sponsor
- Henry Ford Health System
Asthma, Airway Inflammation
Asthma Study Comparing Anti-Inflammatory Effects of 3 Doses of Mometasone Furoate/Formoterol Fumarate and Medium Dose Mometasone Furoate (Study P05122 AM1)(COMPLETED)
This is a 2-week double-blind, placebo-controlled, parallel group study comparing the anti-inflammatory effects of low, medium, and high dose mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) formulation…
- Trial name
- NCT00635882
- Testing
- mometasone furoate/formoterol 100/10 mcg, mometasone furoate/formoterol 200/10 mcg, mometasone furoate/formoterol 400/10 mcg
- Volunteers
- 93 people
- Sponsor
- Organon and Co
Type 1 Diabetes
The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes
The purpose of this study is to learn whether an investigational automated insulin delivery system ("study system") for young children (2 yo to less than 6 yo) with type 1 diabetes can safely improve blood glucose (sometimes…
- Trial name
- NCT04796779
- Testing
- Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
- Where
- 3 sites in United States
- Volunteers
- 102 people
- Sponsor
- Marc Breton
Asthma
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered Dose Inhaler (BDA MDI/PT027) Used 4 Times Daily in Adults and Children 4 Years of Age or Older With Asthma
This is a randomized, double-blind, placebo-controlled, multicenter, parallel group study to compare 2 dose levels of budesonide/albuterol BDA MDI (PT027) to its components budesonide BD MDI (PT008) and albuterol AS MDI (PT007)…
- Trial name
- DENALI (NCT03847896)
- Testing
- Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 160/180 μg (high dose), Budesonide/albuterol sulfate metered dose inhaler / BDA MDI 80/180 μg (low dose), Budesonide metered dose inhaler / BD MDI 160 µg
- Where
- 129 sites in United States, Argentina and 5 more
- Volunteers
- 1,001 people
- Sponsor
- Bond Avillion 2 Development LP
Diabetes Mellitus, Type 2
OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative effectiveness of insulin pump therapy versus multiple daily injections in insulin-taking type 2 Diabetes Mellitus who are sub optimally controlled with multiple daily…
- Trial name
- OpT2mise (NCT01182493)
- Testing
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Where
- 36 sites in United States, Austria and 11 more
- Volunteers
- 331 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
Feasibility Study for Training Pump Naïve Subjects To Use The Paradigm® System And Evaluate Effectiveness
Feasibility study to compare the effectiveness of the Paradigm Sensor Augmented System versus subjects continuing to administer insulin in multiple dose injections.
- Trial name
- STAR2 (NCT00530023)
- Testing
- MiniMed Paradigm REAL-Time System
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- Medtronic MiniMed, Inc.
Asthma
A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma
The purpose of the study is to assess the propellants,1 - Difluoroethane [HFA-152a] (Test) and 1,1,1,2-Tetrafluoroethane [HFA-134a] (Reference) for their potential to cause the airways to tighten when delivered through…
- Trial name
- NCT06702462
- Testing
- HFA-152A propellant, HFA-134A propellant
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- GlaxoSmithKline
Asthma, Exercise-Induced
A Study to Investigate the Effects of PT027 (Budesonide/Albuterol Sulfate) Metered-dose Inhaler Compared With Placebo on Exercise-Induced Bronchoconstriction in Adult Patients With Asthma
The purpose of this Phase III, multicentre, randomized, double-blind, single-dose, 2-period, crossover study is to assess the efficacy and safety of PT027 (budesonide/albuterol sulfate) metered-dose inhaler compared with placebo…
- Trial name
- BREATH (NCT06245551)
- Testing
- Budesonide/albuterol metered-dose inhaler 160/180 μg
- Where
- 6 sites in Russia
- Volunteers
- 64 people
- Sponsor
- AstraZeneca
Asthma
Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers
This study examines the pharmacokinetic profile of Armstrong's proposed Epinephrine Inhalation Aerosol USP, an HFA-MDI (E004), in healthy male and female adult volunteers.
- Trial name
- NCT01143051
- Testing
- epinephrine inhalation aerosol
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Amphastar Pharmaceuticals, Inc.
Asthma
Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects
The primary objective of this study is to evaluate the dose response, efficacy, and safety of 4 different doses of salmeterol Spiromax (6.25, 12.5, 25, and 50 mcg) each combined with a fixed dose of fluticasone propionate (100…
- Trial name
- NCT01772368
- Testing
- Fp MDPI, FS MDPI, Advair Diskus
- Where
- 10 sites in United States
- Volunteers
- 72 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Asthma
Study Comparing Budesonide Hydrofluoroalkane (HFA) vs Chlorofluorocarbon (CFC) Pressurized Metered Dose Inhalers (pMDI) in Patients With Mild to Moderate Asthma
This study is being carried out to see if budesonide with HFA is effective, safe and well tolerated compared with budesonide CFC.
- Trial name
- NCT00667992
- Testing
- Budesonide HFA, Budesonide CFC
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 99 people
- Sponsor
- AstraZeneca
Asthma, COPD
A Patient Handling Study of Mometasone Furoate/Formortoral Fumarate (MF/F) Metered Dose Inhaler (MDI) With an Integrated Dose Counter in Adolescent and Adult Subjects With Asthma or Chronic Obstructive Pulmonary Disease (Study P04703AM1)
This was an open-label, multiple-dose, study of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler (MDI) 100/10 micrograms (mcg) twice daily (BID) (2 puffs of MF/F MDI 50/5 mcg, administered twice a day…
- Trial name
- NCT00604500
- Testing
- SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )
- Volunteers
- 272 people
- Sponsor
- Organon and Co
Asthma
A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With Asthma
This is a randomized, double-blind, multicenter, parallel-group, variable-length study to compare 2 doses of BDA MDI (PT027) with AS MDI (PT007) on the time to first severe asthma exacerbation in adult, adolescent, and pediatric…
- Trial name
- MANDALA (NCT03769090)
- Testing
- Budesonide/albuterol sulfate metered-dose inhaler 160/180 μg, Budesonide/albuterol sulfate metered-dose inhaler 80/180 μg, Albuterol sulfate metered-dose inhaler 180 μg
- Where
- 345 sites in United States, Argentina and 9 more
- Volunteers
- 3,132 people
- Sponsor
- Bond Avillion 2 Development LP
Diabetes Mellitus, Type 2, Obesity
Safety and Efficacy of BI 10773 as add-on to Insulin Regimen in Patients With Type 2 Diabetes Mellitus
This trial will evaluate use of BI 10773 as add-on to insulin regimen alone or with metformin in patients with typr 2 diabetes. Both lowering glucose and HbA1c and reducing the use of insulin in this population would provide…
- Trial name
- NCT01306214
- Testing
- BI 10773
- Where
- 103 sites in United States, Belgium and 12 more
- Volunteers
- 566 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
ACCU-CHEK® Aviva Expert Study: Does Use of a Bolus Advisor Improve Glycemic Control in Patients Not Achieving Optimal Control Using Multiple Daily Injections (MDI)?
This clinical, prospective, randomized, multi-center study determined if the use of an insulin bolus advisor improves glycemic control as measured by a change in HbA1c in patients failing multiple daily injection/intensified…
- Trial name
- ABACUS (NCT01460446)
- Testing
- Aviva Expert blood glucose meter, Aviva Nano blood glucose meter
- Where
- 33 sites in Germany, United Kingdom
- Volunteers
- 218 people
- Sponsor
- Hoffmann-La Roche
Asthma
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
- Trial name
- VATHOS (NCT05202262)
- Testing
- BFF MDI 320/9.6 μg, BFF MDI 160/9.6 μg, BD MDI 320 μg
- Where
- 142 sites in United States, Canada and 5 more
- Volunteers
- 645 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
PT003 MDI Cardiovascular Safety Study
This study is primarily a safety study. The primary and secondary endpoints are based on 24-hour Holter monitor assessments obtained on Day 14 relative to baseline.
- Trial name
- NCT01349803
- Testing
- PT005 MDI, PT001 MDI, PT003 MDI
- Where
- 20 sites in United States, Australia and 1 more
- Volunteers
- 237 people
- Sponsor
- Pearl Therapeutics, Inc.
COPD, Chronic Obstructive Pulmonary Disease
A Study to Assess the Effects of PT001 and PT005 MDI on Specific Image Based Parameters in Subjects With Moderate to Severe COPD
To assess the effect of treatment with Glycopyronnium (GP) MDI administered twice daily (BID) and Formoterol Fumarate (FF) MDI administered BID on specific image-based airway volumes and resistance in subjects with moderate to…
- Trial name
- NCT02937584
- Testing
- GP MDI (PT001) 14.4 μg, FF MDI (PT005) 9.6 μg
- Where
- 2 sites in Belgium
- Volunteers
- 23 people
- Sponsor
- Pearl Therapeutics, Inc.
Asthma, Children
Efficacy and Safety of Increasing Doses of Inhaled Albuterol in Children With Acute Wheezing Episodes
Metered dose inhalers with spacers are devices capable of providing higher rates of lung deposition of drugs such as beta agonists when compared to conventional nebulizers, but there is no consensus about the optimal dose when…
- Trial name
- NCT01323010
- Testing
- Albuterol - Experimental, Albuterol - Control
- Where
- Brazil
- Volunteers
- 119 people
- Sponsor
- University of Sao Paulo